Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results, Beats Estimates By $0.01 EPS

Kymera Therapeutics (NASDAQ:KYMR) released its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01, Briefing.com reports. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.90) earnings per share.

Kymera Therapeutics Trading Up 0.6 %

Shares of NASDAQ KYMR traded up $0.30 during midday trading on Friday, reaching $46.47. 412,696 shares of the stock were exchanged, compared to its average volume of 597,304. The company has a market capitalization of $2.87 billion, a P/E ratio of -19.02 and a beta of 2.21. The stock has a 50 day moving average price of $47.06 and a 200-day moving average price of $40.57. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $53.27.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by company insiders.

Analyst Ratings Changes

KYMR has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Guggenheim boosted their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday. Oppenheimer raised their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.15.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.